Presently, Atezolizumab/Bevacizumab, which is positioned as the first-line drug treatment for HCC, aims to activate antitumor immunity by inhibiting the immune checkpoint molecule PD-L1 and to disrupt tumor vasculature and the TME by inhibiting VEGF-A. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.